R HN (R 6 )n (I) 137 [] The present invention provides a somatostatin receptor subtype 2 agonist. The compound disclosed herein represented by the general formula (I): 5 wherein all symbols have the same meanings as the definitions described in the specification； or a salt thereof is a low-molecular compound having strong agonistic activity for somatostatin receptor subtype 2 and can 10 be orally administered. Therefore, the present compound can be easily administered and can alleviate pain accompanied by the therapy of patients. The present compound also has sufficiently weak hERG inhibitory activity and/or phospholipidosis action relative to the SSTR2 agonistic 15 activity, and thus can suppress or alleviate side effects resulting from the activity/action.
